Drugs / Theanine
Theanine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07220447 | Apr 2026 → Jul 2027 expected | cancer, hematopoietic and lymphoid system neoplasm | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00291070 | Oct 2005 → Jul 2006 | attention deficit-hyperactivity disorder | University of British Columbia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06889584 | Feb → Dec 2025 | — | University of South Carolina | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04749745 Comparator | Jun 2020 → May 2021 | psychiatric disorder | Butler Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04056650 Comparator | Oct 2019 → Dec 2020 | CGF1 | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Theanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220447 ↗ |
| Known as | L-theanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04749745 ↗ |
| Known as | N5-ethyl-L-glutamine | “L-theanine (N5-ethyl-L-glutamine) is the primary psychoactive component uniquely in green tea.” NCT04749745 ↗ |
| Known as | NSC-21308 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039113 ↗ |
| Known as | Suntheanine | “A Double Blind, Randomized Placebo Controlled Clinical Trial Examining the Effects of L-Theanine (Suntheanine®) in Male Child Subjects With Attention Deficit Hyperactivity Disorder” NCT00291070 ↗ |
| Modality | Small molecule | — CHEMBL3039113 ↗ |
| Route | Oral | “Subject will receive 400mg single dose of L-theanine, by oral ingestion with water.” NCT04749745 ↗ |